

ORAL MEDICATION MANAGEMENT OF DIABETES



Class	Names	Mechanism of action	Adverse effects	Teaching
Biguanides PO	Metformin	<ul style="list-style-type: none"> • Increase glucose uptake by muscles, decrease glucose production by liver • Type 2 only 	<ul style="list-style-type: none"> • GI distress • Rare lactic acidosis 	<ul style="list-style-type: none"> • Can be used as monotherapy or in combination • May be used in gestational diabetes • Do not drink alcohol, must be stopped prior to tests w/ iodine contrast. • Teach signs of lactic acidosis.
2nd-generation sulfonylureas PO	Glipizide, glyburide	<ul style="list-style-type: none"> • Increase insulin release from pancreas, may also encourage tissues to be receptive to insulin • Type 2 only 	<ul style="list-style-type: none"> • Low blood sugar • Weight gain 	Can be used as monotherapy or w/ metformin
Meglitinides (glinides) PO	Nateglinide, repaglinide	<ul style="list-style-type: none"> • Increase insulin release from pancreas • Type 2 only 	<ul style="list-style-type: none"> • Low blood sugar • Weight gain 	<ul style="list-style-type: none"> • Can be used as monotherapy or w/ metformin • Shorter-acting than sulfonylureas, taken w/ each meal • Must eat within 30 minute of taking
Thiazolidinediones (glitazones) PO	Pioglitazone, rosiglitazone	<ul style="list-style-type: none"> • Decrease insulin resistance, increase glucose uptake by muscles, may decrease glucose production by liver • Type 2 only 	<ul style="list-style-type: none"> • Sinusitis, URI • Fluid retention • Risk of fractures, increased ovulation 	<ul style="list-style-type: none"> • Can be used as monotherapy or w/ metformin or sulfonylureas • Must be monitored closely for clients w/ heart failure
Alpha-glucosidase inhibitors PO	Acarbose, miglitol	<ul style="list-style-type: none"> • Slow down carbohydrate absorption & digestion; reduce postprandial increase • Type 2 only 	<ul style="list-style-type: none"> • GI distress • Borborygmus 	<ul style="list-style-type: none"> • Can be used as monotherapy or w/ insulin or sulfonylureas • No risk of low blood sugar when used alone
DPP-4 inhibitors (gliptins) PO	Linagliptin, saxagliptin	<ul style="list-style-type: none"> • Slow down the breakdown of incretins by DPP-4; increase insulin release, reduce glucagon release & liver glucose production • Type 2 only 	<ul style="list-style-type: none"> • Pancreatitis • Hypersensitivity reactions 	<ul style="list-style-type: none"> • Can be used as monotherapy or in combination • Teach clients signs of pancreatitis.
Dopamine agonist PO	Bromocriptine	<ul style="list-style-type: none"> • Activate dopamine receptors in the CNS; improve glycemic control, but unknown how exactly • Type 2 only 	<ul style="list-style-type: none"> • Orthostatic hypotension • Exacerbation of psychosis 	<ul style="list-style-type: none"> • Can be used as monotherapy or in combination • Marketed under different name for Parkinson's, hyperprolactinemia
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors PO	Canagliflozin, dapagliflozin	<ul style="list-style-type: none"> • Block SGLT-2 in the tubules of the kidney and increase glucose excretion in urine • Type 2 only 	<ul style="list-style-type: none"> • Genital fungal infections • UTI, polyuria • Orthostatic hypotension 	<ul style="list-style-type: none"> • Can be used as monotherapy or in combination • Ongoing research for use w/ type 1 DM

NOTES

